Sign in
CompletedNo phase

Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder

Key facts

Who runs it
St. Joseph's Healthcare Hamilton
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
12 people enrolled
Started
26 Mar 2024
Ended
17 Apr 2025
Type of study
Interventional
Treatments tested
  • dTMS stimulation via the H4 coil
Record updated
30 March 2026

Who can take part

Age
25 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adult, age 25-65
  • DSM-5 CUD, moderate or higher (4+ DSM-5 symptoms)
  • 4 or more days of cannabis use per week
  • Reports inhalation as one route of administration
  • Treatment-seeking (i.e., self-reported readiness to change of 5 or greater on a 0-10 readiness ruler)
  • Stable domicile and reliable transportation, and willingness to attend in-person visits at SJHH Hamilton

Who cannot take part

  • Co-enrollment in a clinical drug trial
  • Current psychotic symptoms, history of schizophrenia-spectrum disorders or bipolar disorder, or current PTSD
  • Active suicidality (past 3 months) or history of severe suicidality (i.e., requiring hospitalization)
  • Any other mental health condition deemed incompatible by the team
  • High risk alcohol involvement and/or 4+ symptoms of alcohol use disorder
  • Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months
  • Current unstable medical condition (e.g., diabetes)
  • rTMS Contraindications: intracranial or metal implants in the head or nearby regions that cannot be safely removed; history of epilepsy or seizures; pregnancy (female participants only); pacemaker and/or implantable cardioverter-defibrillators)
  • Medication contraindications (e.g., bupropion >300 mg/day due to risk of seizures, benzodiazepine equivalent dose to lorazepam >2 mg/day)
  • History of recurrent headache or migraine (past year)
  • Significant literacy, visual, or hearing problems

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

There is a credible basis for lateral prefrontal cortex and insula deep repetitive transcranial magnetic stimulation (dTMS) stimulation as a treatment for cannabis use disorder (CUD), but no studies to date have examined this. Evidence of benefit could expand the treatment options available for CUD but require randomized controlled trials (RCTs) to evaluate its efficacy. Toward an RCT of this intervention, the proposed study is a phase 1 open-label pilot trial of dTMS for adults with CUD. This study will establish the viability of an H4 protocol constituting an active arm of a future double-blind RCT.

The group in the trial

  • H4 dTMSTreatment being tested

    The participants will receive 18 H4 dTMS sessions over 4-6 weeks as an adjunct to evidence-based standard care for CUD (i.e., motivational interviewing and contingency management).

    Treatment: dTMS stimulation via the H4 coil

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1 Open-Label Pilot Trial of Deep Repetitive Transcranial Stimulation of the Lateral Prefrontal Cortex and Insula for Adults With Moderate-to-Severe Cannabis Use Disorder
Publications
Record updated
30 March 2026